DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Each condition has its own clinical rubric. Pick yours to see the products ranked specifically for it.
Cells respond poorly to insulin — precursor to type 2 diabetes.
Non-alcoholic fatty liver disease, frequently co-occurring with obesity and insulin resistance.
OSA in adults with obesity. Zepbound is FDA-approved for moderate-to-severe OSA with obesity.
BMI ≥ 30. Often accompanied by metabolic comorbidities.
Elevated blood sugar not yet at diabetic levels, often pre-clinical T2D.
Polycystic ovary syndrome — often involves insulin resistance and weight gain.
Chronic condition involving insulin resistance and elevated blood glucose.
Reducing body weight in adults with BMI ≥ 27 with comorbidities or BMI ≥ 30.